Elizabeth E Roughead1, Esther W Chan2, Nam-Kyong Choi3,4, Jenna Griffiths5, Xue-Mei Jin6, Joongyub Lee7, Michio Kimura8, Tomomi Kimura9, Kiyoshi Kubota10,11, Edward Chia-Cheng Lai12, Kenneth Kc Man2, Tuan Anh Nguyen1, Nobuhiro Ooba10, Byung-Joo Park6, Tsugumichi Sato11, Ju-Young Shin13, TongTong Wang5, Ian Ck Wong2,14, Yea-Huei Kao Yang12, Nicole L Pratt1. 1. a Quality Use of Medicines and Pharmacy Research Centre, Sansom Institute for Health Research , University of South Australia , Adelaide , Australia. 2. b Centre for Safe Medication Practice and Research, Department of Pharmacology and Pharmacy , The University of Hong Kong , Hong Kong , Hong kong. 3. c Institute of Environmental Medicine, Medical Research Center , Seoul National University , Seoul , Korea. 4. d Division of Pharmacoepidemiology and Pharmacoeconomics , Brigham and Women's Hospital and Harvard Medical School , Boston , MA , USA. 5. e Marketed Health Products Directorate , Health Products and Food Branch, Health Canada , Ottawa , ON , Canada. 6. f Department of Preventive Medicine , Seoul National University College of Medicine , Seoul , Korea. 7. g Medical Research Collaborating Centre , Seoul National University College of Medicine, Seoul National University Hospital , Seoul , Korea. 8. h Department of Medical Informatics , Hamamatsu University, School of Medicine , Shizuoka , Japan. 9. i Medical Affairs , Astellas Pharma Inc , Tokyo , Japan. 10. j Department of Pharmacoepidemiology , University of Tokyo Graduate School of Medicine , Tokyo , Japan. 11. k NPO Drug Safety Research Unit , Tokyo , Japan. 12. l School of Pharmacy and Institute of Clinical Pharmacy and Pharmaceutical Sciences, Health Outcome Research Centre , National Cheng Kung University , Tainan , Taiwan. 13. m Department of Epidemiology, Biostatistics, and Occupational Health , McGill University , Montreal , Canada. 14. n Research Department of Practice and Policy , UCL School of Pharmacy , London , England.
Abstract
OBJECTIVE: To determine the association between incident proton pump inhibitor (PPI) use and Clostridium difficile infections across multiple countries Method: National data covering the total population in Australia and Korea, the Canadian population over 65 years and a 3 million person random sample data set from Taiwan were assessed, as were data from a worker insurance population and a hospital inpatient/outpatient population in Japan. Sequence symmetry analysis was used to assess the association with oral vancomycin dispensing as the outcome of interest. RESULTS: 54,957 patients were included. Positive associations were observed in Australia; adjusted sequence ratio (ASR) 2.48 (95% CI 1.90, 3.12), Korea ASR 2.15 (95%CI 2.11, 2.19), Canada ASR 1.45 (95% CI 1.16, 1.79), Japan hospital dataset ASR 3.21 (95%CI 2.12, 4.55) and Japan worker insurance dataset ASR 5.40 (95% CI 2.73, 8.75). The pooled result was ASR 2.40 (95%CI 1.88, 3.05) and 3.16 (95%CI 1.95, 5.10) when limited to Japan, Korean and Taiwan. Results did not vary by individual PPI. The temporal analysis showed effects within the first two weeks of PPI initiation. CONCLUSION: Our study confirms the association between PPI initiation and C. difficile infections across countries in the Asia-Pacific region.
OBJECTIVE: To determine the association between incident proton pump inhibitor (PPI) use and Clostridium difficile infections across multiple countries Method: National data covering the total population in Australia and Korea, the Canadian population over 65 years and a 3 million person random sample data set from Taiwan were assessed, as were data from a worker insurance population and a hospital inpatient/outpatient population in Japan. Sequence symmetry analysis was used to assess the association with oral vancomycin dispensing as the outcome of interest. RESULTS: 54,957 patients were included. Positive associations were observed in Australia; adjusted sequence ratio (ASR) 2.48 (95% CI 1.90, 3.12), Korea ASR 2.15 (95%CI 2.11, 2.19), Canada ASR 1.45 (95% CI 1.16, 1.79), Japan hospital dataset ASR 3.21 (95%CI 2.12, 4.55) and Japan worker insurance dataset ASR 5.40 (95% CI 2.73, 8.75). The pooled result was ASR 2.40 (95%CI 1.88, 3.05) and 3.16 (95%CI 1.95, 5.10) when limited to Japan, Korean and Taiwan. Results did not vary by individual PPI. The temporal analysis showed effects within the first two weeks of PPI initiation. CONCLUSION: Our study confirms the association between PPI initiation and C. difficile infections across countries in the Asia-Pacific region.
Authors: Hisham Hussan; Emmanuel Ugbarugba; Michael T Bailey; Kyle Porter; Bradley Needleman; Sabrena Noria; Benjamin O'Donnell; Steven K Clinton Journal: Obes Surg Date: 2018-07 Impact factor: 4.129
Authors: Anca Trifan; Carol Stanciu; Irina Girleanu; Oana Cristina Stoica; Ana Maria Singeap; Roxana Maxim; Stefan Andrei Chiriac; Alin Ciobica; Lucian Boiculese Journal: World J Gastroenterol Date: 2017-09-21 Impact factor: 5.742
Authors: Hongfei Fang; Don C Codipilly; Karthik Ravi; Dale C Ekbom; Jan L Kasperbauer; Magnus Halland Journal: Gastroenterol Res Pract Date: 2018-06-11 Impact factor: 2.260